My research explores how patent systems should address the challenges of inventorship and ownership for AI-generated or AI-assisted drugs. Currently, extending patent protection to such inventions presents significant legal and conceptual challenges. By using the doctrinal, socio-legal, and legal theory research methods, my study critically examines whether these limitations should also apply to AI-generated or AI-assisted drugs. Furthermore, it evaluates which  of the proposed compromise  models for inventorship and ownership of AI-related inventions align closely with the rationale for the patent system, particularly in the context of pharmaceutical drug development.